Literature DB >> 29666812

Tumor progression: the neuronal input.

Marco Arese1,2, Federico Bussolino1,3, Margherita Pergolizzi1,2, Laura Bizzozero1,2, Davide Pascal1,2.   

Abstract

One of the challenges of cancer is its heterogeneity and rapid capacity to adapt. Notwithstanding significant progress in the last decades in genomics and precision medicine, new molecular targets and therapies appear highly necessary. One way to approach this complex problem is to consider cancer in the context of its cellular and molecular microenvironment, which includes nerves. The peripheral nerves, the topic of this review, modulate the biological behavior of the cancer cells and influence tumor progression, including the events related to the metastatic spread of the disease. This mechanism involves the release of neurotransmitters directly into the microenvironment and the activation of the corresponding membrane receptors. While this fact appears to complicate further the molecular landscape of cancer, the neurotransmitters are highly investigated molecules, and often are already targeted by well-developed drugs, a fact that can help finding new therapies at a fraction of the cost and time needed for new medicines (through the so-called drug repurposing). Moreover, the modulation of tumor progression by neurotransmitters can probably explain the long-recognized effects of psychological factors on the burden of cancer. We begin with an introduction on the tumor-nervous-connections and a description of the perineural invasion and neoneurogenesis, the two most important interaction patterns of cancer and nerves. Next, we discuss the most recent data that unequivocally demonstrate the necessity of the nervous system for tumor onset and growth. We introduce the molecular players of the tumor-nervous-connections by citing the role of three main families: neurotropic factors, axon guidance molecules, and neurotransmitters. Finally, we review the role the most important neurotransmitters in tumor biology and we conclude by analyzing the significance of the presented data for cancer therapy, with all the potential advantages and caveats.

Entities:  

Keywords:  Tumor-nervous connections (TNCs); drug repurposing; neurotransmitters; tumor microenvironment

Year:  2018        PMID: 29666812      PMCID: PMC5890045          DOI: 10.21037/atm.2018.01.01

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  132 in total

1.  Dopamine, by acting through its D2 receptor, inhibits insulin-like growth factor-I (IGF-I)-induced gastric cancer cell proliferation via up-regulation of Krüppel-like factor 4 through down-regulation of IGF-IR and AKT phosphorylation.

Authors:  Subhalakshmi Ganguly; Biswarup Basu; Saurav Shome; Tushar Jadhav; Sudipta Roy; Jahar Majumdar; Partha Sarathi Dasgupta; Sujit Basu
Journal:  Am J Pathol       Date:  2010-11-12       Impact factor: 4.307

Review 2.  A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake inhibitors.

Authors:  Daniel P Radin; Parth Patel
Journal:  Biomed Pharmacother       Date:  2017-01-11       Impact factor: 6.529

Review 3.  Neuropeptide Y: its multiple effects in the CNS and potential clinical significance.

Authors:  Eduardo E Benarroch
Journal:  Neurology       Date:  2009-03-17       Impact factor: 9.910

4.  Basal cell carcinoma preferentially arises from stem cells within hair follicle and mechanosensory niches.

Authors:  Shelby C Peterson; Markus Eberl; Alicia N Vagnozzi; Abdelmadjid Belkadi; Natalia A Veniaminova; Monique E Verhaegen; Christopher K Bichakjian; Nicole L Ward; Andrzej A Dlugosz; Sunny Y Wong
Journal:  Cell Stem Cell       Date:  2015-04-02       Impact factor: 24.633

Review 5.  Glioblastoma chemotherapy adjunct via potent serotonin receptor-7 inhibition using currently marketed high-affinity antipsychotic medicines.

Authors:  R E Kast
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

6.  The synaptic proteins β-neurexin and neuroligin synergize with extracellular matrix-binding vascular endothelial growth factor a during zebrafish vascular development.

Authors:  Alberto Rissone; Efrem Foglia; Lorenzo Sangiorgio; Solei Cermenati; Stefania Nicoli; Simona Cimbro; Monica Beltrame; Federico Bussolino; Franco Cotelli; Marco Arese
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04-19       Impact factor: 8.311

Review 7.  Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters.

Authors:  Frank Entschladen; Theodore L Drell; Kerstin Lang; Jan Joseph; Kurt S Zaenker
Journal:  Lancet Oncol       Date:  2004-04       Impact factor: 41.316

Review 8.  Acetylcholine receptor pathway and lung cancer.

Authors:  Frederik B Thunnissen
Journal:  J Thorac Oncol       Date:  2009-08       Impact factor: 15.609

Review 9.  Neuropeptide Y. A novel sympathetic stress hormone and more.

Authors:  Z Zukowska-Grojec
Journal:  Ann N Y Acad Sci       Date:  1995-12-29       Impact factor: 5.691

Review 10.  Novel delivery approaches for cancer therapeutics.

Authors:  Ashim K Mitra; Vibhuti Agrahari; Abhirup Mandal; Kishore Cholkar; Chandramouli Natarajan; Sujay Shah; Mary Joseph; Hoang M Trinh; Ravi Vaishya; Xiaoyan Yang; Yi Hao; Varun Khurana; Dhananjay Pal
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

View more
  17 in total

1.  Importance of semaphorins in cancer immunity.

Authors:  Li-Han Chen; Eric Y Cuang
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 2.  Tumour invasion and dissemination.

Authors:  Ryan Lusby; Philip Dunne; Vijay K Tiwari
Journal:  Biochem Soc Trans       Date:  2022-06-30       Impact factor: 4.919

3.  Comprehensive Characterization of Stage IIIA Non-Small Cell Lung Carcinoma.

Authors:  Neetu Singh; Archana Mishra; Dinesh Kumar Sahu; Mayank Jain; Hari Shyam; Ratnesh Kumar Tripathi; Pratap Shankar; Anil Kumar; Nawazish Alam; Riddhi Jaiswal; Shailendra Kumar
Journal:  Cancer Manag Res       Date:  2020-11-20       Impact factor: 3.989

Review 4.  Beta-Adrenergic Signaling in Tumor Immunology and Immunotherapy.

Authors:  Wei Wang; Xuefang Cao
Journal:  Crit Rev Immunol       Date:  2019       Impact factor: 2.214

Review 5.  Integrating the Tumor Microenvironment into Cancer Therapy.

Authors:  Sabina Sanegre; Federico Lucantoni; Rebeca Burgos-Panadero; Luis de La Cruz-Merino; Rosa Noguera; Tomás Álvaro Naranjo
Journal:  Cancers (Basel)       Date:  2020-06-24       Impact factor: 6.639

6.  Consensus-Expressed CXCL8 and MMP9 Identified by Meta-Analyzed Perineural Invasion Gene Signature in Gastric Cancer Microarray Data.

Authors:  Xiuzhi Jia; Minjia Lu; Chen Rui; Ying Xiao
Journal:  Front Genet       Date:  2019-09-25       Impact factor: 4.599

Review 7.  G Protein-Coupled Receptors (GPCRs)-Mediated Calcium Signaling in Ovarian Cancer: Focus on GPCRs activated by Neurotransmitters and Inflammation-Associated Molecules.

Authors:  Dragoș-Valentin Predescu; Sanda Maria Crețoiu; Dragoș Crețoiu; Luciana Alexandra Pavelescu; Nicolae Suciu; Beatrice Mihaela Radu; Silviu-Cristian Voinea
Journal:  Int J Mol Sci       Date:  2019-11-07       Impact factor: 5.923

Review 8.  Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments.

Authors:  Nguyen Thi Ha; Chang Hoon Lee
Journal:  Cells       Date:  2020-10-25       Impact factor: 6.600

Review 9.  Nerve-sparing radical hysterectomy in the precision surgery for cervical cancer.

Authors:  Noriaki Sakuragi; Gen Murakami; Yosuke Konno; Masanori Kaneuchi; Hidemichi Watari
Journal:  J Gynecol Oncol       Date:  2020-01-21       Impact factor: 4.401

10.  Norepinephrine-CREB1-miR-373 axis promotes progression of colon cancer.

Authors:  Jia Han; Qiuyu Jiang; Ruili Ma; Huahua Zhang; Dongdong Tong; Kaijie Tang; Xiaofei Wang; Lei Ni; Jiyu Miao; Baojun Duan; Yang Yang; Yanke Chen; Fei Wu; Jiming Han; Mengchang Wang; Ni Hou; Chen Huang
Journal:  Mol Oncol       Date:  2020-03-13       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.